{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:42:29Z","timestamp":1781091749982,"version":"3.54.1"},"posted":{"date-parts":[[2024,3,25]]},"group-title":"In Review","reference-count":38,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,3,19]]},"abstract":"<title>Abstract<\/title>\n        <p>Objective: Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on systemic and cardiac inflammation and cardiac fibrosis. \nResearch and Design Methods:  This randomized placebo-controlled clinical trial enrolled 62 adult patients (mean age 62, 17% female) with type 2 diabetes (T2D) without known heart failure.  Subjects were randomized to 12 months of daily 10 mg dapagliflozin or placebo.  For all patients, blood\/plasma samples and cardiac magnetic resonance imaging (CMRI) were obtained at time of randomization and at the end of 12 months. Systemic inflammation was assessed by plasma IL-1B, TNF\u03b1, IL-6 and ketone levels and PBMC mitochondrial respiration, an emerging marker of sterile inflammation. Cardiac fibrosis was assessed by T1 mapping to calculate extracellular volume fraction (ECV); cardiac tissue inflammation was assessed by T2 mapping.\nResults: Between the baseline and 12-month time point, plasma IL-1B was reduced (-1.8 pg\/mL, P=0.003) while ketones were increased (0.26 mM, P=0.0001) in patients randomized to dapagliflozin. PBMC maximal oxygen consumption rate (OCR) decreased over the 12-month period in the placebo group but did not change in patients receiving dapagliflozin (-158.9 pmole\/min\/10<sup>6<\/sup>cells, P=0.0497 vs -45.2 pmole\/min\/10<sup>6<\/sup>cells, P=0.41), a finding consistent with an anti-inflammatory effect of SGLT2i. ECV and T2 relaxation time did not change in both study groups.\nConclusion:  This study demonstrates that 12 months of dapagliflozin reduces IL-1B mediated systemic inflammation but affect cardiac fibrosis in T2D.\nClinical Trial.gov Registration NCT03782259<\/p>","DOI":"10.21203\/rs.3.rs-4132581\/v1","type":"posted-content","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T18:11:37Z","timestamp":1711390297000},"source":"Crossref","is-referenced-by-count":2,"title":["Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure"],"prefix":"10.21203","author":[{"given":"Dennis","family":"Wang","sequence":"first","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Naumova","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Isquith","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sapp","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Anh","family":"Huynh","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Tucker","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Balu","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Voronyuk","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocheng","family":"Chu","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ordovas","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Maynard","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tian","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qiao","family":"Zhao","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8761","reference":[{"issue":"22","key":"ref1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"Lopaschuk GD","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1008922","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials","volume":"9","author":"Scisciola L","year":"2022","unstructured":"Scisciola L, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim SR","year":"2020","unstructured":"Kim SR, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.","journal-title":"Nat Commun"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1021312027486","article-title":"Aging of myocardial collagen","volume":"3","author":"Souza RR","year":"2002","unstructured":"de Souza RR. Aging of myocardial collagen. Biogerontology. 2002;3(6):325\u201335.","journal-title":"Biogerontology"},{"issue":"14","key":"ref8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile MR","year":"2015","unstructured":"Zile MR, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247\u201359.","journal-title":"Circulation"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jacc.2005.09.050","article-title":"The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy","volume":"47","author":"Asbun J","year":"2006","unstructured":"Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006;47(4):693\u2013700.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0046-8177(84)80307-X","article-title":"Pathomorphologic aspects of muscular tissue in diabetes mellitus","volume":"15","author":"Fischer VW","year":"1984","unstructured":"Fischer VW, Barner HB, Larose LS. Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum Pathol. 1984;15(12):1127\u201336.","journal-title":"Hum Pathol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcmg.2015.11.005","article-title":"T1 Mapping: Basic Techniques and Clinical Applications","volume":"9","author":"Taylor AJ","year":"2016","unstructured":"Taylor AJ, et al. T1 Mapping: Basic Techniques and Clinical Applications. JACC Cardiovasc Imaging. 2016;9(1):67\u201381.","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"44937","DOI":"10.1038\/srep44937","article-title":"The Association between Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance T1 Mapping and Myocardial Dysfunction in Diabetic Rabbits","volume":"7","author":"Zeng M","year":"2017","unstructured":"Zeng M, et al. The Association between Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance T1 Mapping and Myocardial Dysfunction in Diabetic Rabbits. Sci Rep. 2017;7:44937.","journal-title":"Sci Rep"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.003073","article-title":"Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure","volume":"8","author":"Bohnen S","year":"2015","unstructured":"Bohnen S et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging, 2015. 8(6).","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1172\/JCI138538","article-title":"Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure","volume":"130","author":"Zhou B","year":"2020","unstructured":"Zhou B, et al. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure. J Clin Invest. 2020;130(11):6054\u201363.","journal-title":"J Clin Invest"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1120\/jacmp.v17i5.6237","article-title":"Patient-specific 17-segment myocardial modeling on a bull's eye map","volume":"17","author":"Jung J","year":"2016","unstructured":"Jung J, et al. Patient-specific 17-segment myocardial modeling on a bull's eye map. J Appl Clin Med Phys. 2016;17(5):453\u201365.","journal-title":"J Appl Clin Med Phys"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa BC","year":"2023","unstructured":"Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia. 2023;66(1):23\u201332.","journal-title":"Diabetologia"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jacbts.2022.06.012","article-title":"Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction","volume":"7","author":"Wang DD","year":"2022","unstructured":"Wang DD, et al. Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction. JACC Basic Transl Sci. 2022;7(12):1183\u201396.","journal-title":"JACC Basic Transl Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1045235","DOI":"10.3389\/fphar.2022.1045235","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wang D","year":"2022","unstructured":"Wang D, et al. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:1045235.","journal-title":"Front Pharmacol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00005-009-0024-y","article-title":"The role of IL-1 in the pathogenesis of heart disease","volume":"57","author":"Bujak M","year":"2009","unstructured":"Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57(3):165\u201376.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1084\/jem.183.3.949","article-title":"Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum","volume":"183","author":"Kumar A","year":"1996","unstructured":"Kumar A, et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949\u201358.","journal-title":"J Exp Med"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ejheart.2003.11.014","article-title":"Differential expression of cytokines in the rat heart in response to sustained volume overload","volume":"6","author":"Dai RP","year":"2004","unstructured":"Dai RP, et al. Differential expression of cytokines in the rat heart in response to sustained volume overload. Eur J Heart Fail. 2004;6(6):693\u2013703.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/jcsm.12763","article-title":"Inhibition of the NLRP3\/IL-1beta axis protects against sepsis-induced cardiomyopathy","volume":"12","author":"Busch K","year":"2021","unstructured":"Busch K, et al. Inhibition of the NLRP3\/IL-1beta axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle. 2021;12(6):1653\u201368.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fphar.2017.00363","article-title":"IL-1beta Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus","volume":"8","author":"Peiro C","year":"2017","unstructured":"Peiro C, et al. IL-1beta Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus. Front Pharmacol. 2017;8:363.","journal-title":"Front Pharmacol"},{"key":"ref24","author":"Abbate A","year":"2013","unstructured":"Abbate A et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol, 2013. 111(10): p. 1394\u2009\u2013\u2009400."},{"key":"ref25","author":"Rommens PM","year":"1991","unstructured":"Rommens PM, Goffin J. [Osteosynthesis of the dens axis fracture]. Acta Chir Belg, 1991. 91(4): p. 169\u2009\u2013\u200974."},{"issue":"9","key":"ref26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate A","year":"2020","unstructured":"Abbate A, et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020;126(9):1260\u201380.","journal-title":"Circ Res"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"14709","DOI":"10.1038\/s41598-019-51298-3","article-title":"Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients","volume":"9","author":"Shirakawa R","year":"2019","unstructured":"Shirakawa R, et al. Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients. Sci Rep. 2019;9(1):14709.","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1038\/srep10229","article-title":"Mitochondrial respiratory dysfunctions of blood mononuclear cells link with cardiac disturbance in patients with early-stage heart failure","volume":"5","author":"Li P","year":"2015","unstructured":"Li P, et al. Mitochondrial respiratory dysfunctions of blood mononuclear cells link with cardiac disturbance in patients with early-stage heart failure. Sci Rep. 2015;5:10229.","journal-title":"Sci Rep"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1172\/JCI120845","article-title":"Mitochondrial fidelity and metabolic agility control immune cell fate and function","volume":"128","author":"Sack MN","year":"2018","unstructured":"Sack MN. Mitochondrial fidelity and metabolic agility control immune cell fate and function. J Clin Invest. 2018;128(9):3651\u201361.","journal-title":"J Clin Invest"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1172\/JCI83260","article-title":"Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects","volume":"125","author":"Traba J","year":"2015","unstructured":"Traba J, et al. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J Clin Invest. 2015;125(12):4592\u2013600.","journal-title":"J Clin Invest"},{"key":"ref31","volume-title":"Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes","author":"Julla JB","year":"2023","unstructured":"Julla JB, et al. Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. Circ Res; 2023."},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie MR","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat Rev Cardiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin B","year":"2014","unstructured":"Lin B, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang N","year":"2019","unstructured":"Zhang N, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2019;18(1):107.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCRESAHA.116.307974","article-title":"T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review","volume":"119","author":"Puntmann VO","year":"2016","unstructured":"Puntmann VO, et al. T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. Circ Res. 2016;119(2):277\u201399.","journal-title":"Circ Res"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"15348","DOI":"10.1038\/s41598-019-51949-5","article-title":"Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus","volume":"9","author":"Hsu JC","year":"2019","unstructured":"Hsu JC, et al. Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus. Sci Rep. 2019;9(1):15348.","journal-title":"Sci Rep"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ehf2.12505","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions","volume":"6","author":"Lan NSR","year":"2019","unstructured":"Lan NSR, et al. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927\u201335.","journal-title":"ESC Heart Fail"},{"issue":"16","key":"ref38","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis","volume":"70","author":"Grani C","year":"2017","unstructured":"Grani C, et al. Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol. 2017;70(16):1964\u201376.","journal-title":"J Am Coll Cardiol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4132581\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4132581\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T19:46:34Z","timestamp":1718999194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4132581\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":38,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4132581\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12933-024-02294-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,3,25]]},"subtype":"preprint"}}